Pembrolizumab May Be Preferable to Chemo in Certain Patients
NEW YORK (Reuters Health) – Pembrolizumab may have an edge on chemotherapy for microsatellite instability-high (MSI-H) advanced gastric or gastroesophageal-junction […]
NEW YORK (Reuters Health) – Olamkicept, an interleukin (IL)-6 trans-signaling inhibitor, was well tolerated and induced a clinical response in […] Biosimilar drugs are a prescription alternative that could save billions of dollars and revolutionize the American healthcare system. One of […]biologics
Olamkicept May Induce Response in IBD Patients
Biosimilar Drugs Could Save Money and Lives. So Why Don’t We Use Them?